Hemovent expands Series A

Hemovent said today it received an undisclosed amount of funding as part of an oversubscribed Series A expansion round. The funds came from all existing investors, the Aachen, Germany-based company said, as well as newly invested 1st Capital Partner. Hemovent said that the funding comes shortly after it completed the 1st series of in vivo trials of its artificial lung technology platform which it is developing for a range of indications including extracorporeal CO2 removal and extracorporeal life support. “The fact that all Hemovent investors participated in this new round, and that 1st Capital Partner is an experienced life sciences investment firm known for investing sizable funds in both early-stage and follow-on rounds, bears strong testimony to the opportunity ahead of us as well as the efficient progress we have been able to make to date. Our investors understand Hemovent’s platform is positioned to disrupt a billion-dollar market. In vivo trials have already validated our platform’s superior blood-handling behavior and efficiency parameters compared to standard ECMO. We expect when Hemovent is available by mid-next year it will immediately drive ECMO usage not only for ECLS but also as an effective therapy for respiratory failure indications including ECCO2R protocols,” CEO Christof Lenz said in a prepared statement. Last February, Hemovent said it raised $6m in a Series A round to support its portable extra corporeal membrane oxygenat...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Respiratory Hemovent Source Type: news

Related Links:

Authors: Hsin MKY, Wong CF, Yan SW, Fan KY, Ho CKL, Bhatia I, Au TWK Abstract Clinical lung transplant was first performed in Hong Kong in 1995. In the early years, the volume of activity was very low. There has been a clear trend of increasing volume in the past few years. The recipient pathology is very different from the International Society for Heart and Lung Transplantation (ISHLT) database, with complete absence of cystic fibrosis and alpha-1-antitrypsin deficiency, and a predominance of diseases of the pulmonary circulation. Lymphangioleiomyomatosis (LAM) has a much higher representation on the waiting list...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Authors: Hsin M, Au T Abstract Lung transplantation is a proven treatment for selected patients with end-stage lung disease. However, the number of patients on the transplant waiting list far exceeds the number of available donor lungs, resulting in waiting list morbidity and mortality. The problem is further exacerbated by the low utilisation rate of available donor lungs, for fear of selecting a damaged lung and the resultant primary graft dysfunction. In the past decade, ex vivo lung perfusion (EVLP) has become part of standard lung transplant clinical practice in Canada and Europe, and it has been shown to impr...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ConclusionOur series confirmed that CCPRCC has an indolent clinical behavior. When the diagnosis is made in a high-grade renal tumor, it should be carefully re-confirmed using cytogenetic or genomic methods.
Source: Journal of the Chinese Medical Association - Category: General Medicine Source Type: research
Ruud H. Knols, Nicolas Fischer, Dario Kohlbrenner, Anastasios Manettas, Eling D. de Bruin
Source: Frontiers in Physiology - Category: Physiology Source Type: research
The U.S. Food and Drug Administration (FDA) has cleared artificial intelligence...Read more on AuntMinnie.comRelated Reading: Mirada upgrades radiation treatment software Mirada introduces AI software for radiation oncology Optellum, Mirada present lung cancer study at RSNA 2017 Mirada's deep-learning contours match human-drawn contours Mirada showcases XD:PACS at RSNA 2016
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
A 39-year-old non-smoker woman was admitted in the thoracic oncology unit of the Montpellier Academic Hospital in June 2017 for investigation of multiple lung consolidations, fever, and respiratory failure. She was followed-up since infancy for a cystic fibrosis with cystic fibrosis transmembrane conductance regulator (CFTR) mutation ( ΔF508-CFTR). Two years ago, a lung allograft was decided, owing to rapid onset of respiratory function impairment, and she received a bi-pulmonary transplant. According to the donor database, the lung transplant was removed from a 57-year-old woman with a 30 pack-year smoking history.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
In this study, we investigated the role of RN in IR-induced lung injury. To study IR-induced cell-death, we simulated LTx procedure using our cell culture model with human lung epithelial (BEAS-2B) cells. After 18 h of cold ischemic time (CIT) followed by reperfusion, caspase-independent cell-death, mitochondrial-ROS production and mitochondrial-membrane permeability were significantly increased. ALLN (calpain inhibitor) or necrostatin-1 (Nec-1; RIPK1 inhibitor) reduced these changes. ALLN altered RIPK1/RIPK3 expression and MLKL phosphorylation, whereas Nec-1 did not change calpain/calpastatin expression. Furthermore, STAT...
Source: Am J Physiol Lung Ce... - Category: Respiratory Medicine Authors: Tags: Am J Physiol Lung Cell Mol Physiol Source Type: research
Clinical Transplantation,Volume 0, Issue ja, -Not available-.
Source: Clinical Transplantation - Category: Transplant Surgery Authors: Source Type: research
We present here the incidence and long-term outcome of BOS occurring after HSCT in an extended cohort of 110 patients monitored with home spirometry.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Research letters Source Type: research
More News: Funding | Germany Health | Lung Transplant | Respiratory Medicine